Azenta Reports Q4 CY2024 Earnings, Revenue Exceeds Expectations

Q4 CY2024 Highlights:

* Revenue: $147.5 million vs. analyst estimates of $146 million (4.4% year-over-year decline, 1.1% beat)
* Adjusted EPS: $0.05 vs. analyst estimates of $0.06 (in line)
* Adjusted EBITDA: $13 million vs. analyst estimates of $13.59 million (8.8% margin, 4.4% miss)
* Operating Margin: -7.7%, up from -10.5% in the same quarter last year
* Free Cash Flow Margin: 14.9%, up from 9.4% in the same quarter last year

Company Overview:

Azenta (NASDAQ: AZTA) provides services for life sciences research and biopharmaceutical applications, including sample management, cold chain logistics, and storage.

Sales Growth:

* Annual sales growth: -4.4% over the last five years
* Annualized revenue growth: 4.5% over the last two years
* Q4 CY2024 revenue: $147.5 million, missing expectations

Adjusted Operating Margin:

* Average adjusted operating margin: 4.1% over the last five years
* Five-year trend: -10.3 percentage points decline
* Two-year trend: -2.7 percentage points decline
* Q4 CY2024 adjusted operating margin: 8.8%, up from -7.7% in the same quarter last year

Earnings Per Share (EPS):

* Five-year annual EPS decline: 11.5%
* Q4 CY2024 EPS: $0.05, up from $0.02 in the same quarter last year but missing analyst estimates
* Expected full-year EPS growth: 14.7%

Key Takeaways:

* Revenue beat analyst estimates, while EBITDA missed.
* Operating margin improved significantly, indicating increased efficiency.
* EPS missed expectations, despite year-over-year growth.
* Sell-side analysts project a 7% revenue decline in the next 12 months.